Clinical Trials Browser

Phase NA × Recruiting × selinexor × Clear all

NCT06853678 2025-03-03

Second-line Immunotherapy for ES-SCLC

Phase NA Recruiting

Extensive Stage Small Cell Lung Cancer (ES-SCLC)